Antibody response and plasma Aβ1-40 levels in young Microcebus murinus primates immunized with Aβ1-42 and its derivatives

Vaccine

Volumn 27, Issue 7, 2009, Pages 957-964

  Trouche, Stéphanie G ^a,b,c   Asuni, Ayodeji ^d   Rouland, Sylvie ^a,b,c   Wisniewski, Thomas ^d   Frangione, Blas ^d   Verdier, Jean Michel ^a,b,c   Sigurdsson, Einar M ^d   Mestre Francés, Nadine ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b University of Montpellier   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alum; Amyloid ; Immunization; Lemur; Microcebus murinus; Primate

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AMYLOID BETA 1-30 [E18 E19]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; K6ABETA1-30; K6ABETA1-30 [E18 E19]; TAU PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROSIMIAN; WEIGHT GAIN;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; BODY WEIGHT; BRAIN; CHEIROGALEIDAE; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; PEPTIDE FRAGMENTS; PLASMA;

EID: 58549089731     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.012     Document Type: Article

References (38)

1. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., and Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159 2 (2001) 439-447
2. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 12 (2001) 1236-1237
3. Singh H., and Raghava G.P. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19 8 (2003) 1009-1014
4. Khalili-Shirazi A., Quaratino S., Londei M., et al. Protein conformation significantly influences immune responses to prion protein. J Immunol 174 6 (2005) 3256-3263
5. Sigurdsson E.M., Knudsen E., Asuni A., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24 28 (2004) 6277-6282
6. Scholtzova H., Wisniewski T., Ahlawat S., et al. Safety of potential vaccines for Alzheimer's disease [Abstract]. Soc Neurosci Abstr 227 (2002) 1
7. Asuni A.A., Boutajangout A., Scholtzova H., et al. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci 24 9 (2006) 2530-2542
8. Vermes L.M. [Cerebrospinal fluid proteins: III. Normal values of immunoglobulins G, A and M (variations related to race, sex and age)]. Arq Neuropsiquiatr 41 1 (1983) 25-49
9. Nerenberg S.T., and Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 86 5 (1975) 887-898
10. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
11. Sigurdsson E.M. Immunotherapy for conformational diseases. Curr Pharm Des 12 20 (2006) 2569-2585
12. Wisniewski T., and Sigurdsson E.M. Therapeutic approaches for prion and Alzheimer's diseases 2. FEBS J 274 15 (2007) 3784-3798
13. Lemere C.A., Beierschmitt A., Iglesias M., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165 1 (2004) 283-297
14. Gandy S., DeMattos R.B., Lemere C.A., et al. Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 18 1 (2004) 44-46
15. Head E., Pop V., Vasilevko V., et al. A two-year study with fibrillar beta-amyloid (A beta) immunization in aged canines: effects on cognitive function and brain A beta 1. J Neurosci 28 14 (2008) 3555-3566
16. Bons N., Mestre N., and Petter A. Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate Microcebus murinus. Neurobiol Aging 13 1 (1992) 99-105
17. Mestre-Frances N., Keller E., Calenda A., Barelli H., Checler F., and Bons N. Immunohistochemical analysis of cerebral cortical and vascular lesions in the primate Microcebus murinus reveal distinct amyloid beta1-42 and beta1-40 immunoreactivity profiles. Neurobiol Dis 7 1 (2000) 1-8
18. Giannakopoulos P., Silhol S., Jallageas V., et al. Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur Microcebus murinus. Acta Neuropathol (Berl) 94 2 (1997) 131-139
19. Asuni A.A., Boutajangout A., Quartermain D., and Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27 34 (2007) 9115-9129
20. Sigurdsson E.M., Quartermain D., and Boutajangout A. Tau immunotherapy prevents cognitive decline and clears pathological tau in a tangle mouse model [Abstract]. Alzheimer's Demen 4 4 (2008) T191-T192
21. Roder H.M., and Hutton M.L. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin Ther Targets 11 4 (2007) 435-442
22. Sigurdsson E.M. Histological staining of amyloid-beta in mouse brains. Methods Mol Biol 299 (2005) 299-308
23. Sigurdsson E.M., Lorens S.A., Hejna M.J., Dong X.W., and Lee J.M. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging 17 6 (1996) 893-901
24. Head E., Barrett E.G., Murphy M.P., et al. Immunization with fibrillar A beta(1-42) in young and aged canines: antibody generation and characteristics, and effects on CSF and brain A beta 6. Vaccine 24 15 (2006) 2824-2834
25. Hyman B.T., Smith C., Buldyrev I., et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49 6 (2001) 808-810
26. Szabo P., Relkin N., and Weksler M.E. Natural human antibodies to amyloid beta peptide 3. Autoimmun Rev 7 6 (2008) 415-420
27. Neff F., Wei X., Nolker C., Bacher M., Du Y.S., and Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders 2. Autoimmun Rev 7 6 (2008) 501-507
28. Vincent R.P., Ashrafian H., and le Roux C.W. Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity 2. Nat Clin Practice Gastroenterol Hepatol 5 5 (2008) 268-277
29. Leverone J.F., Spooner E.T., Lehman H.K., Clements J.D., and Lemere C.A. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Vaccine 21 17-18 (2003) 2197-2206
30. Hara H., Monsonego A., Yuasa K., et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 6 5 (2004) 483-488
31. Seabrook T.J., Thomas K., Jiang L., et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging (2006)
32. Seabrook T.J., Jiang L., Thomas K.E., and Lemere C.A. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. J Neuroinflammation 3 1 (2006) 14
33. Frenkel D., Dewachter I., Van Leuven F., and Solomon B. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 21 11-12 (2003) 1060-1065
34. Lavie V., Becker M., Cohen-Kupiec R., et al. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24 1 (2004) 105-113
35. Agadjanyan M.G., Ghochikyan A., Petrushina I., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174 3 (2005) 1580-1586
36. Maier M., Seabrook T.J., Lazo N.D., et al. Short amyloid-beta (A beta) immunogens reduce cerebral A beta load and learning deficits in an Alzheimer's disease mouse model in the absence of an A beta-specific cellular immune response. J Neurosci 26 18 (2006) 4717-4728
37. Zhou J., Fonseca M.I., Kayed R., et al. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2 (2005) 28
38. Fagan T. Trial Troika-Immunotherapy Interrupted, Lipitor Lags, Dimebon Delivers; 2008. Alzheimer Research Forum. April 25, 2008. http://www.alzforum.org/new/detail.asp?id=1807 [accessed April 28, 2008].